A gene called ABCB1, which will be understood to play a part in resistance to the chemotherapy drug in ovarian cancers causes resistance researchers at the University of Dundee have found.
Girls with ovarian cancer can be treated with a combination of drug and carboplatin, but another group of drugs called PARP inhibitors are a standard choice if the cancer becomes immune as mentioned at diabetes discussion forum.
When the Dundee team treated chemotherapy-resistant ovarian cancer cells grown in the laboratory with PARP inhibitors that were specific, they found the cells used ABCB1 to endure the treatment in exactly the same manner they do.
Dr Gillian Smith, who headed the research, said: "Drug resistance is an important complication for many ovarian cancer patients.
"Our study demonstrates a significant resistance mechanism that is common to drugs used regularly in the practice and to new drugs which are being examined in clinical trials
"Raising our understanding of resistance mechanisms will enable us to develop tests to spot drug resistance more readily and to ensure patients are given the most suitable drugs.
"Understanding the biology of drug-resistant cancers could also result in the growth of new treatments that block cancer's getaway, making them susceptible to treatment again."
The findings are released in the British Journal of Cancer.
"It demonstrates for the very first time the same mechanism that creates ovarian cancer to become immune to drug also applies to some PARP inhibitors and other chemotherapy treatments.